Allspring Global Investments
CCCC icon

Allspring Global Investments’s C4 Therapeutics CCCC Stock Holding History

Allspring Global Investments’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-725
Closed -$4.28K – 2791
2022
Q4 		$4.28K Sell
725
-16
-2% -$133 ﹤0.01% 2794
2022
Q3 		$6K Sell
741
-1,394
-65% -$14.5K ﹤0.01% 2768
2022
Q2 		$16K Sell
2,135
-14,146
-87% -$124K ﹤0.01% 2526
2022
Q1 		$394K Buy
16,281
+614
+4% +$14.9K ﹤0.01% 2330
2021
Q4 		$504K Buy
+15,667
New +$620K ﹤0.01% 2290

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allspring Global Investments's CCCC Position: Q1 2023 in Review

Allspring Global Investments sold out of C4 Therapeutics (CCCC) in Q1 2023, closing a stake of 725 shares — an estimated $4.28K sold.

Allspring Global Investments first reported a position in CCCC in Q4 2021 and held it in 5 quarters. The position peaked at $504K in Q4 2021. 120 funds tracked by Wall St. Rank hold CCCC as of Q1 2023.

  • Allspring Global Investments reported no remaining C4 Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Allspring Global Investments sold 725 C4 Therapeutics shares in Q1 2023, an estimated $4.28K.
  • Allspring Global Investments first reported a position in C4 Therapeutics in Q4 2021 and held it in 5 quarters.
  • Allspring Global Investments's C4 Therapeutics position peaked at $504K in Q4 2021.
  • 120 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2023.

Based on Allspring Global Investments's 13F filing for Q1 2023, filed 13 Apr 2023.